Gilead Raday
Chief Operating Officer presso REDHILL BIOPHARMA LTD.
Patrimonio netto: 27 115 $ in data 31/03/2024
Profilo
Gilead Raday is currently the Chief Operating Officer at RedHill Biopharma Ltd.
He previously served as the Chief Executive Officer at Sepal Pharma Plc in 2010.
From 2005 to 2013, he was a Director at Celsus Therapeutics Plc.
He also held director positions at Vaccine Research International Plc, TK-Signal Ltd., and Vidac Pharma Ltd.
Additionally, Mr. Raday was a Partner at Charles Street Securities Europe LLP from 2004 to 2008.
He obtained a graduate degree from the University of Cambridge and both undergraduate and graduate degrees from The Hebrew University of Jerusalem.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
REDHILL BIOPHARMA LTD.
0.00% | 21/04/2023 | 511 600 ( 0.00% ) | 27 115 $ | 31/03/2024 |
Posizioni attive di Gilead Raday
Società | Posizione | Inizio |
---|---|---|
REDHILL BIOPHARMA LTD. | Chief Operating Officer | 01/04/2016 |
Precedenti posizioni note di Gilead Raday
Società | Posizione | Fine |
---|---|---|
Sepal Pharma Plc
Sepal Pharma Plc Pharmaceuticals: MajorHealth Technology Sepal Pharma Plc is a British company that manufactures pharmaceutical preparations. | Chief Executive Officer | 01/10/2010 |
Charles Street Securities Europe LLP
Charles Street Securities Europe LLP Investment ManagersFinance Charles Street Securities Europe LLP (Charles Street) is a private equity firm founded in 1984. The firm is headquartered in the London, United Kingdom. | Private Equity Investor | 01/01/2008 |
Vaccine Research International Plc
Vaccine Research International Plc Miscellaneous Commercial ServicesCommercial Services Vaccine Research International Plc is a British company that focuses on conducting clinical trials to evaluate the effectiveness of vaccine SA75 in preventing staphylococcal infections in hospital patients and the wider community. | Director/Board Member | - |
Vidac Pharma Ltd.
Vidac Pharma Ltd. Pharmaceuticals: MajorHealth Technology Vidac Pharma Ltd. manufactures pharmaceutical products. It is a clinical stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases. The company was founded in 2011 by Max Herzberg is headquartered in Jerusalem, Israel. | Director/Board Member | - |
Celsus Therapeutics Plc
Celsus Therapeutics Plc Pharmaceuticals: MajorHealth Technology Celsus Therapeutics Plc is a drug development company, which focuses on developing novel, first-in-class, non-steroidal, synthetic anti-inflammatory drugs and multi-functional anti-inflammatory drugs. The company main clinical candidates are MRX-5, MRX-6, MRX-4, CFX-1 and OPX-1. Celsus Therapeutics was founded on October 7, 2004 and is headquartered in London, the United Kingdom. | Director/Board Member | - |
Formazione di Gilead Raday
University of Cambridge | Graduate Degree |
The Hebrew University of Jerusalem | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
REDHILL BIOPHARMA LTD. | Health Technology |
Aziende private | 6 |
---|---|
Celsus Therapeutics Plc
Celsus Therapeutics Plc Pharmaceuticals: MajorHealth Technology Celsus Therapeutics Plc is a drug development company, which focuses on developing novel, first-in-class, non-steroidal, synthetic anti-inflammatory drugs and multi-functional anti-inflammatory drugs. The company main clinical candidates are MRX-5, MRX-6, MRX-4, CFX-1 and OPX-1. Celsus Therapeutics was founded on October 7, 2004 and is headquartered in London, the United Kingdom. | Health Technology |
Charles Street Securities Europe LLP
Charles Street Securities Europe LLP Investment ManagersFinance Charles Street Securities Europe LLP (Charles Street) is a private equity firm founded in 1984. The firm is headquartered in the London, United Kingdom. | Finance |
Vaccine Research International Plc
Vaccine Research International Plc Miscellaneous Commercial ServicesCommercial Services Vaccine Research International Plc is a British company that focuses on conducting clinical trials to evaluate the effectiveness of vaccine SA75 in preventing staphylococcal infections in hospital patients and the wider community. | Commercial Services |
TK-Signal Ltd.
TK-Signal Ltd. Medical SpecialtiesHealth Technology TK-Signal Ltd. develops therapies for hematological cancer applications. Its product TKS040, which manage and trace focused drug therapy for cancer patients. The firm also develops various radiopharmaceutical molecular imaging tracers, specific molecular radiotherapy agents, and radioactive biomarkers to diagnose and monitor cancerous tumors. TK-Signal was founded in 2001 by Eyal Mishani and Alexander Levitzki and is headquartered in Jerusalem, Israel. | Health Technology |
Sepal Pharma Plc
Sepal Pharma Plc Pharmaceuticals: MajorHealth Technology Sepal Pharma Plc is a British company that manufactures pharmaceutical preparations. | Health Technology |
Vidac Pharma Ltd.
Vidac Pharma Ltd. Pharmaceuticals: MajorHealth Technology Vidac Pharma Ltd. manufactures pharmaceutical products. It is a clinical stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases. The company was founded in 2011 by Max Herzberg is headquartered in Jerusalem, Israel. | Health Technology |
- Borsa valori
- Insiders
- Gilead Raday